The role of neuropeptide Y, orexin-A, and ghrelin in differentiating unipolar and bipolar depression: a preliminary study

References

• APA. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s synopsis of psychiatry behavioural sciences/clinical psychiatry. 11th ed. Philadelphia (PA): Lippincott Williams and Wilkins/Wolters Kluwer; 2015.
   Google Scholar
• Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–174.
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Walker P, Puzantian VR, et al. Bipolar outcome in the course of depressive illness: phenomenologic, familial, and pharmacologic predictors. J Affect Disord. 1983;5(2):115–128.
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Wilhelm K, Parker G, et al. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry. 2001;62(3):212–216.
   PubMed Web of Science ®Google Scholar
• Nuñez NA, Comai S, Dumitrescu E, et al. Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study. BMC Psychiatry. 2018;18(1):68.
   PubMedGoogle Scholar
• Parker G, Hadzi-Pavlovic D, Eyers K. Melancholia: a disorder of movement and mood: a phenomenological and neurobiological review. Cambridge: Cambridge University Press; 1996.
   Google Scholar
• Ghaemi SN, Hsu DJ, Ko JY, et al. Bipolar spectrum disorder: a pilot study. Psychopathology. 2004;37(5):222–226.
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10(1 Pt 2):144–152.
   PubMed Web of Science ®Google Scholar
• Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the international society for bipolar disorders biomarkers task force. Aust NZ J Psychiatry. 2013;47(4):321–332.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585.
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–1263.
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7(28):28.
   PubMedGoogle Scholar
• Yamuy J, Fung SJ, Xi M, et al. Hypocretinergic control of spinal cord motoneurons. J Neurosci. 2004;24(23):5336–5345.
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–1562.
   PubMed Web of Science ®Google Scholar
• Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology. 2001;25(5 Suppl):S5–S13.
   PubMedGoogle Scholar
• Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50(3):381–388.
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190(2–3):240–243.
   PubMed Web of Science ®Google Scholar
• Tsuchimine S, Hattori K, Ota M, et al. Reduced plasma orexin-A levels in patients with bipolar disorder. NDT. 2019;15:2221–2230.
   Google Scholar
• TschöP M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707–709.
   PubMed Web of Science ®Google Scholar
• Kluge M, Schüssler P, Schmid D, et al. Ghrelin plasma levels are not altered in major depression. Neuropsychobiology. 2009;59(4):199–204.
   PubMed Web of Science ®Google Scholar
• Barim AO, Aydin S, Colak R, et al. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem. 2009;42(10–11):1076–1081.
   PubMed Web of Science ®Google Scholar
• Tunçel ÖK, Sarısoy G, Bilgici B, et al. Adipocytokines and ghrelin level of bipolar patients from manic episode to euthymic episode. Nord J Psychiatry. 2018;72(2):150–156.
   PubMed Web of Science ®Google Scholar
• Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463(1–3):235–272.
   PubMed Web of Science ®Google Scholar
• Heilig M, Widerlöv E. Neuropeptide Y: an overview of Central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand. 1990;82(2):95–114.
   PubMed Web of Science ®Google Scholar
• Heilig M, Zachrisson O, Thorsell A, et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res. 2004;38(2):113–121.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Onishi H, Koide S, et al. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci Lett. 1996;216(1):57–60.
   PubMed Web of Science ®Google Scholar
• Gjerris A, Widerlöv E, Werdelin L, et al. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J Psychiatry Neurosci. 1992;17(1):23–27.
   PubMed Web of Science ®Google Scholar
• Hou C, Jia F, Liu Y, et al. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res. 2006;1095(1):154–158.
   PubMed Web of Science ®Google Scholar
• Sandberg JV, Jakobsson J, Pålsson E, et al. Low neuropeptide Y in cerebrospinal fluid in bipolar patients is associated with previous and prospective suicide attempts. Eur Neuropsychopharmacol. 2014;24(12):1907–1915.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545.
   PubMed Web of Science ®Google Scholar
• Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71–83.
   PubMed Web of Science ®Google Scholar
• Tholin S, Rasmussen F, Tynelius P, et al. Genetic and environmental influences on eating behavior: the Swedish young male twins study. Am J Clin Nutr. 2005;81(3):564–569.
   PubMed Web of Science ®Google Scholar
• Cull JG, Gill WS. Suicide Probability Scale (SPS). Los Angeles (CA): Western Psychological Services; 1982.
   Google Scholar
• Valdez GR, Koob GF. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav. 2004;79(4):671–689.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57(10):470–484.
   PubMed Web of Science ®Google Scholar
• Sommer WH, Lidström J, Sun H, et al. Human NPY promoter variation rs16147:T > C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat. 2010;31(8):E1594–E608.
   PubMed Web of Science ®Google Scholar
• Czermak C, Hauger R, Drevets WC, et al. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression. J Affect Disord. 2008;110(3):277–281.
   PubMed Web of Science ®Google Scholar
• Martinez JM, Garakani A, Yehuda R, et al. Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety. 2012;29(1):32–38.
   PubMed Web of Science ®Google Scholar
• Soleimani L, Oquendo MA, Sullivan GM, et al. Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma. Int J Neuropsychopharmacol. 2015;18(1):pyu023.
   Web of Science ®Google Scholar
• Widerlöv E, Lindström L, Wahlestedt C, et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res. 1988;22(1):69–79.
   PubMed Web of Science ®Google Scholar
• Baker DG, Bertram TM, Patel PM, et al. Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology. 2013;38(10):2378–2382.
   PubMed Web of Science ®Google Scholar
• Dötsch J, Adelmann M, Englaro P, et al. Relation of leptin and neuropeptide Y in human blood and cerebrospinal fluid. J Neurol Sci. 1997;151(2):185–188.
   PubMed Web of Science ®Google Scholar
• Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J Neurosci Res. 2020;98(5):950–963.
   PubMed Web of Science ®Google Scholar
• Nikisch G, Ågren H, Eap CB, et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol. 2005;8(3):403–410.
   PubMed Web of Science ®Google Scholar
• Nikisch G, Mathé AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatr. 2008;23(5):356–359.
   PubMed Web of Science ®Google Scholar
• Mathé A, Jousisto‐Hanson J, Stenfors C, et al. Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J Neurosci Res. 1990;26(2):233–237.
   PubMed Web of Science ®Google Scholar
• Zachrisson O, Mathé AA, Stenfors C, et al. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. Neurosci Lett. 1995;194(1–2):89–92.
   PubMed Web of Science ®Google Scholar
• Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96–104.
   PubMed Web of Science ®Google Scholar
• Eban-Rothschild A, Giardino WJ, de Lecea L. To sleep or not to sleep: neuronal and ecological insights. Curr Opin Neurobiol. 2017;44:132–138.
   PubMed Web of Science ®Google Scholar
• Hori H, Koga N, Hidese S, et al. 24-h activity rhythm and sleep in depressed outpatients. J Psychiatr Res. 2016;77:27–34.
   PubMed Web of Science ®Google Scholar
• Ozsoy S, Besirli A, Abdulrezzak U, et al. Serum ghrelin and leptin levels in patients with depression and the effects of treatment. Psychiatry Investig. 2014;11(2):167–172.
   PubMed Web of Science ®Google Scholar
• Kurt E, Guler O, Serteser M, et al. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neurosci Lett. 2007;426(1):49–53.
   PubMed Web of Science ®Google Scholar
• Pinar M, Gulsun M, Tasci I, et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):135–139.
   PubMed Web of Science ®Google Scholar
• Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832–844.
   PubMed Web of Science ®Google Scholar
• Tunçel ÖK, Akbaş S, Bilgici B. Increased ghrelin levels and unchanged adipocytokine levels in major depressive disorder. J Child Adolesc Psychopharmacol. 2016;26(8):733–739.
   PubMed Web of Science ®Google Scholar
• Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 2005;30(1):106–110.
   PubMed Web of Science ®Google Scholar
• Stip E, Lungu O, Anselmo K, et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry. 2012;2(6):e128.
   PubMedGoogle Scholar
• Greco R, Latini G, Chiarelli F, et al. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. 2005;65(11):1808–1809.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Pyne-Geithman GJ, Ekhator NN, et al. Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology. 2010;35(7):1001–1007.
   PubMed Web of Science ®Google Scholar